Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
These results demonstrated that using V116 in adults aged ≥ 65 years in the US can prevent a substantial number of PD cases and deaths while remaining highly favorable economically over a wide range of inputs and scenarios.
Authors
- Elamin H. Elbasha (ORCID: https://orcid.org/0000-0002-9993-8036)
- Kwame Owusu‐Edusei (ORCID: https://orcid.org/0000-0002-4519-2857)
- Zinan Yi (ORCID: https://orcid.org/0009-0002-4997-3121)
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Decision Sciences (United States) (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1007/s40121-024-01067-1
- Citations
- 9
- Primary Topic
- Pneumonia and Respiratory Infections
- Type
- article
- Field-Weighted Citation Impact
- 3.48